Every material Form 8-K Nkarta, Inc. has filed with the SEC since May 12, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Nkarta reported initial clinical data for NKX019, its allogeneic CAR NK cell therapy candidate, in myositis and systemic sclerosis, based on small patient groups with limited follow-up. Among 40 patients treated across five indications, the company reported no deaths and no treatment discontinuations due to adverse events, and it has amended its dosing schedule and plans upcoming FDA discussions on registrational pathways.
Myositis: 5 of 6 patients (83%) at the 4 billion-cell dose with at least three months of follow-up achieved moderate or major Total Improvement Score responses.
Systemic sclerosis: 6 of 7 patients (86%) at the 4 billion-cell dose reached an rCRISS-25 response or greater by Day 90; 5 of 7 (71%) reached rCRISS-50.
Safety: infusion-related reactions occurred in five patients (12.5%), mostly grade 1, and all resolved within 24 to 48 hours.
Nkarta amended protocols to dose on Days 0, 2 and 4, plans to evaluate 6 billion cells per dose, and expects to report additional follow-up in the first half of 2027.
Nkarta, Inc. announced it will host a webcast on Monday, November 9, 2026, at 8:00 a.m. Eastern Time to review initial clinical data for its NKX019 cell therapy candidate in myositis and systemic sclerosis, presented at the American College of Rheumatology Convergence 2026. The filing contains no financial results, and the company did not disclose the clinical data itself in this document, so shareholders will learn the results at the webcast.
Webcast set for Monday, November 9, 2026, at 8:00 a.m. ET
Initial data covers NKX019 in myositis and systemic sclerosis under the Ntrust program
Data to be presented at ACR Convergence 2026 in Orlando; replay to be archived on Nkarta's investor website
Nkarta reported third-quarter 2026 results, with a net loss of $33.3 million, or $0.45 per share, compared with a net loss of $21.7 million, or $0.29 per share, a year earlier. The company said its $216.0 million in cash, cash equivalents, restricted cash and investments as of September 30, 2026, is expected to fund operations into 2029. Higher research and development spending drove the larger loss, and shareholders face continued losses while the company's lead candidate is still in clinical trials.
Q3 2026 net loss of $33.3 million ($0.45 per share), up from $21.7 million ($0.29 per share) in Q3 2025
R&D expenses rose to $29.5 million from $20.2 million; G&A expenses fell to $6.3 million from $7.1 million
Cash and investments were $216.0 million on September 30, 2026, down from $295.1 million on December 31, 2025
Initial NKX019 clinical data to be presented at ACR Convergence 2026, with an oral presentation on November 8
Nkarta reported second-quarter 2026 results in a press release furnished as Exhibit 99.1. The clinical-stage biotechnology company posted a net loss of $40.4 million, or $0.54 per share, up from $23.0 million, or $0.31 per share, a year earlier, as total operating expenses rose to $43.1 million. The company said its $243.2 million in cash and investments is expected to fund operations into 2029.
Net loss of $40.4 million, or $0.54 per share, for Q2 2026, versus $23.0 million, or $0.31 per share, for Q2 2025.
Net loss included $8.0 million of impairment of right-of-use assets, leasehold improvements and other equipment.
R&D expenses were $29.0 million and G&A expenses were $14.1 million in Q2 2026, versus $6.4 million G&A a year earlier.
Cash, cash equivalents, restricted cash and investments were $243.2 million on June 30, 2026, expected to fund operations into 2029.
Nkarta reported first quarter 2026 results with a net loss of $27.8 million, or $0.37 per share, down from $32.0 million, or $0.43 per share, a year earlier. G&A expenses fell to $5.9 million from $12.4 million, while cash, cash equivalents and investments declined to $266.7 million from $295.1 million at year-end 2025, and the company expects its current operating plan to be funded into 2029.
Net loss of $27.8 million ($0.37 per share) for Q1 2026, versus $32.0 million ($0.43 per share) in Q1 2025
R&D expenses were $25.0 million, up from $24.2 million; G&A expenses fell to $5.9 million from $12.4 million
Cash and investments were $266.7 million on March 31, 2026, down from $295.1 million on December 31, 2025
Company expects current cash to fund its operating plan into 2029
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Nkarta, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →